{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:28:27Z","timestamp":1768462107611,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T00:00:00Z","timestamp":1549670400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00415-019-09234-y","type":"journal-article","created":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T11:08:57Z","timestamp":1549710537000},"page":"1073-1078","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment"],"prefix":"10.1007","volume":"266","author":[{"given":"Quentin","family":"Riller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Cotteret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helga","family":"Junot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neila","family":"Benameur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Haroche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Mathian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Hie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Miyara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Tilleul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahir","family":"Amoura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7610-4995","authenticated-orcid":false,"given":"Fleur","family":"Cohen Aubart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,9]]},"reference":[{"key":"9234_CR1","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/1756-185X.13305","volume":"21","author":"SC Bae","year":"2018","unstructured":"Bae SC, Lee YH (2018) Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials. Int J Rheum Dis 21:922\u2013929","journal-title":"Int J Rheum Dis"},{"key":"9234_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","volume":"174","author":"RP Baughman","year":"2006","unstructured":"Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, Muller-Quernheim J, Schlenker-Herceg R, Flavin S, Lo KH, Oemar B, Barnathan ES, Sarcoidosis I (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174:795\u2013802","journal-title":"Am J Respir Crit Care Med"},{"key":"9234_CR3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00415-017-8444-9","volume":"264","author":"F Cohen Aubart","year":"2017","unstructured":"Cohen Aubart F, Bouvry D, Galanaud D, Dehais C, Mathey G, Psimaras D, Haroche J, Pottier C, Hie M, Mathian A, Devilliers H, Nunes H, Valeyre D, Amoura Z (2017) Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol 264:891\u2013897","journal-title":"J Neurol"},{"key":"9234_CR4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1634\/theoncologist.2017-0126","volume":"23","author":"F Farhat","year":"2018","unstructured":"Farhat F, Torres A, Park W, de Lima Lopes G, Mudad R, Ikpeazu C, Abi Aad S (2018) The concept of biosimilars: from characterization to evolution\u2014a narrative review. Oncologist 23:346\u2013352","journal-title":"Oncologist"},{"key":"9234_CR5","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","volume":"89","author":"JM Gelfand","year":"2017","unstructured":"Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, Koth LL, Hauser SL, Dierkhising J, Vu N, Sriram S, Moses H, Bagnato F, Kaufmann JA, Ammah DJ, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S (2017) Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology 89:2092\u20132100","journal-title":"Neurology"},{"key":"9234_CR6","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1001\/jama.2017.5202","volume":"317","author":"A Hakim","year":"2017","unstructured":"Hakim A, Ross JS (2017) Obstacles to the adoption of biosimilars for chronic diseases. JAMA 317:2163\u20132164","journal-title":"JAMA"},{"key":"9234_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.semarthrit.2017.03.005","volume":"47","author":"Y Jamilloux","year":"2017","unstructured":"Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, Maucort-Boulch D, Marquet A, Perard L, Bouillet L, Deroux A, Abad S, Bielefeld P, Bouvry D, Andre M, Noel N, Bienvenu B, Proux A, Vukusic S, Bodaghi B, Sarrot-Reynauld F, Iwaz J, Amoura Z, Broussolle C, Cacoub P, Saadoun D, Valeyre D, Seve P, Groupe Sarcoidose F (2017) Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients. Semin Arthritis Rheum 47:288\u2013294","journal-title":"Semin Arthritis Rheum"},{"key":"9234_CR8","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK Jorgensen","year":"2017","unstructured":"Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mork C, Jahnsen J, Kvien TK, Nor-Switch Study Group (2017) Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 389:2304\u20132316","journal-title":"Lancet"},{"key":"9234_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","volume":"77","author":"J Kay","year":"2018","unstructured":"Kay J, Schoels MM, Dorner T, Emery P, Kvien TK, Smolen JS, Breedveld FC, Task Force on the Use of Biosimilars to Treat Rheumatological Diseases (2018) Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis 77:165\u2013174","journal-title":"Ann Rheum Dis"},{"key":"9234_CR10","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMhle1800125","volume":"378","author":"GH Lyman","year":"2018","unstructured":"Lyman GH, Zon R, Harvey RD, Schilsky RL (2018) Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 378:2036\u20132044","journal-title":"N Engl J Med"},{"key":"9234_CR11","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, Mikazane H, Gutierrez-Urena S, Lim M, Lee YA, Lee SJ, Kim H, Yoo DH, Braun J (2013) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72:1605\u20131612","journal-title":"Ann Rheum Dis"},{"key":"9234_CR12","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.rmed.2018.02.009","volume":"138S","author":"MC Schimmelpennink","year":"2018","unstructured":"Schimmelpennink MC, Vorselaars ADM, van Beek FT, Crommelin HA, Deneer VHM, Keijsers RGM, Veltkamp M (2018) Efficacy and safety of infliximab biosimilar Inflectra((R)) in severe sarcoidosis. Respir Med 138S:S7\u2013S13","journal-title":"Respir Med"},{"key":"9234_CR13","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1001\/jamaneurol.2018.2295","volume":"75","author":"BJ Stern","year":"2018","unstructured":"Stern BJ, Royal W III, Gelfand JM, Clifford DB, Tavee J, Pawate S, Berger JR, Aksamit AJ, Krumholz A, Pardo CA, Moller DR, Judson MA, Drent M, Baughman RP (2018) Definition and consensus diagnostic criteria for neurosarcoidosis: from the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol 75:1546\u20131553","journal-title":"JAMA Neurol"},{"key":"9234_CR14","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","volume":"383","author":"D Valeyre","year":"2014","unstructured":"Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Muller-Quernheim J (2014) Sarcoidosis. Lancet 383:1155\u20131167","journal-title":"Lancet"},{"key":"9234_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1183\/09031936.00227014","volume":"46","author":"AD Vorselaars","year":"2015","unstructured":"Vorselaars AD, Crommelin HA, Deneer VH, Meek B, Claessen AM, Keijsers RG, van Moorsel CH, Grutters JC (2015) Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J 46:175\u2013185","journal-title":"Eur Respir J"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09234-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09234-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09234-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T19:04:51Z","timestamp":1581188691000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09234-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,9]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["9234"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09234-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,9]]},"assertion":[{"value":"8 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare they have no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was conducted according to the Declaration of Helsinki. Accorded to the French law (Loi Jard\u00e9 2012), a study that do not change the care of patients does not need to be submitted to a loca IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the patients have been informed and signed written consent to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}